ArticleJournal of pediatric surgery2020
Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis.
Article in Journal of pediatric surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Long-term outcomes of children with ulcerative colitis after acute severe colitis: A GETAID pédiatrique multicenter study.Journal of pediatric gastroenterology and nutrition · 2026Article
- Unusual endoscopic remission in an anti-tumor necrosis factor refractory case of severe ulcerative colitis during upadacitinib therapy.JPGN reports · 2026Article
- Global patterns of disease progression in inflammatory bowel disease: a comprehensive synthesis of contemporary population-based cohorts.Gastroenterology report · 2026Review
- Mucosal disease activity may predict response to fecal microbiota transplantation in patients with ulcerative colitis.Pediatric research · 2025Article
- Long-term outcome of pediatric acute severe colitis: A prospective 5-year follow-up of the PRASCO trial.Journal of pediatric gastroenterology and nutrition · 2025Article
- Immunotherapy withdrawal by step-down to mesalamine in pediatric patients with ulcerative colitis.JPGN reports · 2024Article
- Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review.Translational pediatrics · 2023Review
- A Single-Center Study of Long-Term Effectiveness of Vedolizumab in Anti-TNF Refractory Pediatric Inflammatory Bowel Disease.JPGN reports · 2023Article
- Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation.Journal of Crohn's & colitis · 2022Article
- Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis.JPGN reports · 2022Article
- Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine.Frontiers in pediatrics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
background/purposeClinical outcomes in pediatric ulcerative colitis (UC) in the era of biologic agents are poorly defined. We aimed to describe risk factors for colectomy in pediatric UC in the era of infliximab therapy.
methodsWe reviewed 217 pediatric patients at Texas Children's Hospital with newly diagnosed UC between 2003 and 2015; 117 had a minimum of 5 years of follow-up. Extent of disease at diagnosis, medication exposure, the presence of extraintestinal manifestations (EIMs), and need for surgery were noted.
resultsAverage length of follow up was 5.02 ± 2.27 years. Forty-two percent presented with pancolitis. Infliximab was used in 39%, immunomodulators in 65%, and steroids in 89% of patients. EIMs occurred in 24.9% of patients. The cumulative rate of colectomy was 12.9% at 5 years. Children presenting as E2 (Paris Classification) and children prescribed oral steroid monotherapy at diagnosis progressed to surgery faster than any other group. Of the children who received infliximab, females and children less than 5 years old were less likely to respond to therapy.
conclusionsThe natural course of pediatric UC remains aggressive despite the addition of infliximab to the standard of care and suggests a need for early aggressive clinical intervention. LEVEL-OF-EVIDENCE RATING: Level IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.